Comparative Pharmacology
Head-to-head clinical analysis: LOCOID LIPOCREAM versus MICORT HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOCOID LIPOCREAM versus MICORT HC.
LOCOID LIPOCREAM vs MICORT-HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Locoid Lipocream contains hydrocortisone butyrate, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and subsequent synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production, reduces mast cell degranulation, and decreases vascular permeability.
Topical corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release, thereby exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Apply a thin layer to affected area twice daily. Maximum duration of continuous treatment: 4 weeks.
Topical: Apply a thin film to affected area 2-4 times daily. Rectal: Insert one suppository (25 mg) rectally twice daily (morning and evening) for 2-3 weeks, then taper as needed.
None Documented
None Documented
Terminal elimination half-life: ~6-8 hours (hydrocortisone butyrate); clinical context: supports twice-daily dosing
Terminal elimination half-life is 1.5-2.5 hours; clinical duration of action is longer due to genomic effects lasting 8-12 hours.
Renal: ~1.5% as unchanged hydrocortisone butyrate and metabolites; Biliary/fecal: ~85% as metabolites
Renal (approximately 70% as inactive metabolites, <5% unchanged); fecal (approximately 30%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid